| ¿µ¹® | brain tumor | ÇÑ±Û | ³úÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼ »ý±ä Á¾¾çÀ» ÁöĪÇÏ´Â ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀÎ µÎ°³°¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù. ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀÎ µÎ°³°¿¡¼ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀÎ Á¶Á÷À» ¾Ð¹ÚÇÏ°Ô µÇ°í, µÎ°³°³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Ư¡¿¡ ÀÇÇØ¼ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀÎ ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇÏ´Â ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù. |
||
| ¿µ¹® | epithelial tumor | ÇÑ±Û | »óÇǼºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»ó »ç¶÷ÀÇ Á¶Á÷Àº üǥ¸éÀ» µ¤´Â ¿ªÇÒÀ» ÇÏ´Â Á¶Á÷°ú, ÁÖ·Î ¹ß»ý±âÀÇ Á߹迱¿¡¼ ºÐÈÇÑ °£¿±Á¶Á÷¿¡¼ À¯·¡ÇÏ´Â °áÇÕÁ¶Á÷, »À, ¿¬°ñ, Áö¹æ, ±ÙÀ°, Ç÷°ü µîÀÇ Á¶Á÷ÀÇ µÎ °èÅëÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ÀüÀÚ¸¦ »óÇǼº Á¶Á÷, ÈÄÀÚ¸¦ ºñ»óÇǼº Á¶Á÷À̶ó ÇÏ¸ç ±× °¢°¢À» ±¸¼ºÇÏ´Â ¼¼Æ÷¸¦ »óÇǼº ¼¼Æ÷, ºñ»óÇǼ¼Æ÷¶ó ÃÑĪÇÑ´Ù. »óÇǼº ¼¼Æ÷¿¡¼ ±â¿øÇÏ´Â Á¾¾çÀÌ »óÇǼº Á¾¾çÀ̸ç, ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ³ª Ç÷·ù, ¸²ÇÁÀÇ Á¶Á÷À» Ÿ°í ¿ø°Å¸®ÀÇ Àå±â·Î À̵¿ÇÏÁö ¾Ê´Â ¾ç¼ºÁ¾¾ç¿¡´Â ¼±Á¾, À¯µÎÁ¾ µîÀÌ ÀÖ°í ¾ç¼º°ú ¹Ý´ë·Î ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ, ¿ø°ÝÀå±â·Î ÀüÀÌÇÏ´Â ¾Ç¼ºÁ¾¾çÀ» ¸ðµÎ ÅëĪÇÏ¿© ¾ÏÁ¾(carcinoma)À̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | medullary tumor | ÇÑ±Û | ¼öÁú¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | ¾ÏÀÇ º´¸®ÇÐÀûÀÎ ºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼ ³ªÅ¸³ª´Âµ¥ ÁÖ·Î °©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼ º¸ÀδÙ. |
||
| ¿µ¹® | malignant tumor | ÇÑ±Û | ¾Ç¼ºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû-ÈÇÐÀû-»ý¹°ÇÐÀûÀÎ ¹ß¾Ï ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ Çü¼ºµÇ´Â Á¾¾ç. ¹«Á¦ÇÑÀÇ ¼¼Æ÷ºÐ¿·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§Á¶Á÷À» ÆÄ±«-ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² ÈÇй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ Ä«ÄʽþƸ¦ÀÏÀ¸ÄÑ Á×À½À» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù. |
||
| ¿µ¹® | benign tumor | ÇÑ±Û | ¾ç¼ºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¹ßÀ°¼Óµµ°¡ ¿Ï¸¸ÇÏ¿© ¼ºÀå¿¡ ÇѰ谡 ÀÖ°í, ÁÖÀ§¿ÍÀÇ °æ°è°¡ ¸íÈ®Çϸç, ´Ù¸¥ Á¶Á÷À¸·Î ÆÛÁöÁö ¾ÊÀ¸¸ç, ħÀ±À̳ª ÀüÀ̸¦ ÀÏÀ¸Å°Áö ¾Æ´ÏÇÏ´Â Á¾¾ç. ¼¶À¯Á¾À̳ª Áö¹æÁ¾ µûÀ§°¡ ÀüÇüÀûÀÎ ¿¹ÀÌ´Ù. ¾ç¼ºÁ¾¾çÀº Á¾¾çÀÌ Á¸ÀçÇÑ´Ù°í ÇØµµ 1Â÷ÀûÀ¸·Î ¼÷ÁÖÀÇ »ý¸íÀ» À§ÇùÇÏ´Â ÀÏÀº ¾ø´Ù. ¾ç¼ºÁ¾¾çÀÇ ¹ßÀ°Çü½ÄÀº ÁÖÀ§ÀÇ Á¶Á÷°£¿¡ ¿Õ·¡ÇÏ´Â ÀÏÀÌ ¾øÀÌ ÁÖÀ§ÀÇ Á¶Á÷À» ¹Ð¾î³»¸ç Áõ½ÄÇÑ´Ù. ¹ßÀ°¼Óµµ´Â ¿Ï¸¸Çϸç ÀüÀÌÇϰųª ÀýÁ¦ ÈÄ Àç¹ßÇÏ´Â ÀÏÀÌ ±ØÈ÷ µå¹°´Ù. Á¾¾ç¼ººÐÀº º¯ÀÌüÀ̱ä ÇÏÁö¸¸ ¼º¼÷ÇÑ Á¤»ó¼¼Æ÷¿Í °ÅÀÇ ´Ù¸¥ °ÍÀÌ ¾ø´Ù. Àü½Å¿¡ ´ëÇÑ ¿µÇâÀº ¾Ç¼ºÁ¾¾çÀÇ °æ¿ì ¾î´À Á¤µµ ¹ßÀ°ÇßÀ» ¶§ Àü½ÅÀÇ ¿µ¾ç»óŰ¡ ¼Õ»óµÇ¾î Ä«Äʽþư¡ µÇÁö¸¸ ¾ç¼ºÁ¾¾çÀÇ °æ¿ì ÀÌ·± ÀÏÀº °ÅÀÇ ¾ø´Ù. ¾ç¼ºÁ¾¾ç°ú ¾Ç¼ºÁ¾¾çÀÇ ¼º»óÀÇ Â÷ÀÌ¿¡ ¾ö¹ÐÇÑ °æ°è´Â ¾ø°í, °æ°è°æº¯À¸·Î º¸ÀÌ´Â Á¾¾çµµ ÀÖ´Ù. |
||
| SSAA | sicca syndrome associated antigen A; Sjogren syndrome-associated antigen A; syringomyelia secondary ... |
|---|---|
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
| TA | alkaline tuberculin; arterial tension; axillary temperature; tactile afferent; Takayasu arteritis; t... |
| HLA | histocompatibility leukocyte antigen; histocompatibility locus antigen; homologous leukocyte antibod... |
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| graft rejection | <haematology, immunology> When donated bone marrow infused during a bone marrow transplant is rejected by the patients body or does not take. (16 Dec 1997) |
|---|---|
| chronic allograft rejection | Immunologically mediated damage to the allograft, typically a kidney allograft, manifested by diffuse interstitial fibrosis glomerular changes, typically membranous and sclerotic in nature, as well as intimal fibrosis of the blood vessels with tubular atrophy and loss of tubular structures. (05 Mar 2000) |
| chronic rejection | A transplant rejection occurring after a few or many months, mainly from persisting serum antibody action. (05 Mar 2000) |
| primary rejection | A rejection occurring more than seven days after transplantation, mainly from a cellular immune response. (05 Mar 2000) |
| second set rejection | An accelerated rejection of a transplant that occurs when an individual has been previously sensitised to the graft. (05 Mar 2000) |
| hyperacute rejection | A rejection that usually develops in less than one hour from the implantation of a vascular graft, a form of antibody-mediated, usually irreversible damage to a transplanted organ, particularly the kidney, manifested predominantly by diffuse thrombotic lesions, usually confined to the organ itself and only rarely disseminated, for skin allograft rejection of this type, see white graft. (05 Mar 2000) |
| first-set rejection | Allograft transplantation between two organisms not previously sensitised to the graft tissue. Necrosis of the graft usually occurs within 10 days of transplantation. (05 Mar 2000) |
| adeno-associated virus | <virology> A genus of viruses in the family Parvoviridae which are all defective viruses (unable to replicate by themselves) and depend on the co-infection of their host cell by other, nondefective viruses to help them replicate. (09 Oct 1997) |
| aids-associated nephropathy | Renal syndrome in human immunodeficiency virus-infected patients characterised by nephrotic syndrome, severe proteinuria, focal and segmental glomerulosclerosis with distinctive tubular and interstitial changes, enlarged kidneys, and peculiar tubuloreticular structures. The syndrome is distinct from heroin-associated nephropathy as well as other forms of kidney disease seen in HIV-infected patients. (12 Dec 1998) |
| antigens, tumour-associated, carbohydrate | Carbohydrate antigens expressed by malignant tissue. They are useful as tumour markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. (12 Dec 1998) |
| associated | Joined as a companion; brought into association; accompanying; combined. <physiology> Associated movements, consensual movements which accompany voluntary efforts without our consciousness. Source: Websters Dictionary (01 Mar 1998) |
| associated antagonist | One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action. (05 Mar 2000) |
| associated macrophage | A mature macrophage in an active metabolic state that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines. (05 Mar 2000) |
| associated movements | Normal involuntary limp movements that accompany voluntary movement, e.g., arm swing with walking. (05 Mar 2000) |
| p60 tumour necrosis factor receptor-associated kinase | <enzyme> Interacts with and causes phosphorylation of the cytoplasmic domain of the tnf receptor Registry number: EC 2.7.10.- Synonym: p60 tnf receptor-associated kinase, p60-trak (26 Jun 1999) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|